+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial



Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial



Lancet. Oncology 10(8): 785-793



Stage IIIB non-small-cell lung cancer (NSCLC) is usually thought to be unresectable, and is managed with chemotherapy with or without radiotherapy. However, selected patients might benefit from surgical resection after neoadjuvant chemotherapy and radiotherapy. The aim of this multicentre, phase II trial was to assess the efficacy and toxicity of a neoadjuvant chemotherapy and radiotherapy followed by surgery in patients with technically operable stage IIIB NSCLC. Between September, 2001, and May, 2006, patients with pathologically proven and technically resectable stage IIIB NSCLC were sequentially treated with three cycles of neoadjuvant chemotherapy (cisplatin with docetaxel), immediately followed by accelerated concomitant boost radiotherapy (44 Gy in 22 fractions) and definitive surgery. The primary endpoint was event-free survival at 12 months. Efficacy analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00030810. 46 patients were enrolled, with a median age of 60 years (range 28-70). 13 (28%) patients had N3 disease, 36 (78%) had T4 disease. All patients received chemotherapy; 35 (76%) patients received radiotherapy. The main toxicities during chemotherapy were neutropenia (25 patients [54%] at grade 3 or 4) and febrile neutropenia (nine [20%]); the main toxicity after radiotherapy was oesophagitis (ten patients [29%]; nine grade 2, one grade 3). 35 patients (76%) underwent surgery, with pneumonectomy in 17 patients. A complete (R0) resection was achieved in 27 patients. Peri-operative complications occurred in 14 patients, including two deaths (30-day mortality 5.7%). Seven patients required a second surgical intervention. Pathological mediastinal downstaging was seen in 11 of the 28 patients who had lymph-node involvement at enrolment, a complete pathological response was seen in six patients. Event-free survival at 12 months was 54% (95% CI 39-67). After a median follow-up of 58 months, the median overall survival was 29 months (95% CI 16.1-NA), with survival at 1, 3, and 5 years of 67% (95% CI 52-79), 47% (32-61), and 40% (24-55). A treatment strategy of neoadjuvant chemotherapy and radiotherapy followed by surgery is feasible in selected patients. Toxicity is considerable, but manageable. Survival compares favourably with historical results of combined treatment for less advanced stage IIIA disease. Swiss Group for Clinical Cancer Research (SAKK) and an unrestricted educational grant by Sanofi-Aventis (Switzerland).

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054566859

Download citation: RISBibTeXText

PMID: 19604722

DOI: 10.1016/s1470-2045(09)70172-x


Related references

Definitive Hyperfractionated Accelerated (AHF) Radiochemotherapy (CRT) Versus Neoadjuvant AHF-CRT and Surgery (S) for Patients (pts) With Operable Stage IIIA(N2)/Selected IIIB Non-small-Cell Lung Cancer (NSCLC) Following Induction Chemotherapy (IND-C): Results From a Multicenter Phase III Study. International Journal of Radiation Oncology*biology*physics 90(1): S146-S147, 2014

Preliminary results of a phase II study of neoadjuvant radiotherapy concurrent with weekly paclitaxel and carboplatin , followed by surgery in patients with stage IIB-IIIB non small cell lung cancer. European Journal of Cancer 37(Suppl. 6): S52, 2001

Neoadjuvant chemotherapy followed by preoperative radiochemotherapy (hfRTCT) plus surgery or surgery plus postoperative radiotherapy in stage III non-small cell lung cancer: Results of a randomized phase III trial of the German lung cancer cooperative group. International Journal of Radiation Oncology*biology*physics 60: S130-S130, 2004

Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial. Lung Cancer 58(2): 238-245, 2007

A phase II trial of gemcitabine-cisplatin-paclitaxel chemotherapy as neoadjuvant treatment of unresectable stage IIIA -IIIB non-small cell lung cancer Preliminary results. International Journal of Cancer Suppl. (13): 413, 2002

Phase II trial of sequential chemotherapy followed by chemoradiation, surgery, and postoperative chemotherapy for the treatment of stage IIIA/IIIB non-small-cell lung cancer. Clinical Lung Cancer 8(2): 122-129, 2006

Neoadjuvant chemotherapy followed by surgery in stage IIIa/IIIb non-small cell lung cancer. European Journal of Cancer 37(Suppl. 6): S54, 2001

Neo-adjuvant chemotherapy followed by surgery and/or radiotherapy in patients with stage IIIB non-small cell lung cancer (NSCLC), preliminary data. Lung Cancer 21: S25-S26, 1998

Sequential treatment with vindesine-ifosfamide-platinum (VIP) chemotherapy followed by platinum sensitized radiotherapy in stage IIIB non-small cell lung cancer: a phase II trial. Lung Cancer 22(1): 45-53, 1998

Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): a pilot phase I/II trial. Annals of Oncology 13(3): 403-411, 2002

Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. Journal of Clinical Oncology 10(8): 1237-1244, 1992

Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trial. Lung Cancer 34(1): 115-123, 2001

Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer. Journal of Thoracic Oncology 2(10): 927-932, 2007

Concurrent chemotherapy and short course radiotherapy in patients with stage IIIA to IIIB non-small cell lung cancer not eligible for radical treatment: results of a randomized phase II study. Journal of Thoracic Oncology 5(8): 1255-1262, 2010

Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). Journal of Clinical Oncology 33(35): 4194-4201, 2015